Opendoor’s Bold Move Against Short Sellers
Opendoor fights back against short sellers with tradable warrants, turning a massive stock loss into a record comeback.
Already have an account? Sign in.
Opendoor fights back against short sellers with tradable warrants, turning a massive stock loss into a record comeback.
Surgery Partners shares hit five-year low after cutting full-year guidance due to weaker patient volumes and insurance payment trends in Q3 2025.
Vera Therapeutics has submitted its application for atacicept, a potential breakthrough IgAN treatment that successfully reduced proteinuria in the Phase 3 ORIGIN 3 trial.
Innate Pharma is moving forward with the TELLOMAK 3 trial for lacutamab in advanced cutaneous T-cell lymphomas (CTCL), including Sézary syndrome (SS) and Mycosis fungoides (MF).